ATR-X
|
WikiDoc Resources for ATR-X |
|
Articles |
|---|
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on ATR-X at Clinical Trials.gov Clinical Trials on ATR-X at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on ATR-X
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Directions to Hospitals Treating ATR-X Risk calculators and risk factors for ATR-X
|
|
Healthcare Provider Resources |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
ATR-X is used to refer to Alpha-thalassemia X-Linked Mental Retardation, a condition caused by a mutated gene. Females with this mutated gene have no specific signs or features. Male carriers tend to be moderately mentally retarded and have physical characteristics including excessively prominent lips, a depressed nasal bridge, and a small head size.[1]